Beijing Biostar Pharmaceuticals (2563) Stock Overview
A synthetic biology-driven biopharmaceutical company, engages in the development, manufacturing, and commercialization of oncology products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
2563 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Beijing Biostar Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.80 |
| 52 Week High | HK$10.58 |
| 52 Week Low | HK$2.40 |
| Beta | 0 |
| 1 Month Change | -4.52% |
| 3 Month Change | -1.04% |
| 1 Year Change | -51.09% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -81.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2563 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 10.5% | 3.5% | -2.9% |
| 1Y | -51.1% | -5.3% | -4.6% |
Return vs Industry: 2563 underperformed the Hong Kong Biotechs industry which returned -5.3% over the past year.
Return vs Market: 2563 underperformed the Hong Kong Market which returned -4.6% over the past year.
Price Volatility
| 2563 volatility | |
|---|---|
| 2563 Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.2% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 2563's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2563's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 134 | Rongguo Qiu | www.biostar-pharm.com |
Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the development, manufacturing, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injections for metastatic breast cancer, breast cancer neoadjuvant, non-small cell lung cancer, pancreatic cancer, non-small cell lung cancer brain metastasis, and breast cancer brain metastasis indications; and Utidelone capsules for metastasis breast cancer, triple-negative breast cancer adjuvant intensive, first line gastric cancer, platinum-resistant ovarian cancer, and soft tissue sarcoma indications. It is also involved in the development of Utidelone antibody drug conjugate in preclinical studies; and BG22, BG18, and BG44 products for solid tumor indications in preclinical studies.
Beijing Biostar Pharmaceuticals Co., Ltd. Fundamentals Summary
| 2563 fundamental statistics | |
|---|---|
| Market cap | HK$1.39b |
| Earnings (TTM) | -HK$151.91m |
| Revenue (TTM) | HK$38.56m |
Is 2563 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2563 income statement (TTM) | |
|---|---|
| Revenue | CN¥33.36m |
| Cost of Revenue | CN¥2.62m |
| Gross Profit | CN¥30.74m |
| Other Expenses | CN¥162.17m |
| Earnings | -CN¥131.44m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 92.13% |
| Net Profit Margin | -393.94% |
| Debt/Equity Ratio | 0% |
How did 2563 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/02 12:57 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beijing Biostar Pharmaceuticals Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhishun Siu | CCB International Securities Limited |